TrialNature communications2022

Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial.

I'ah Donovan-Banfield et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.